PubMed Journals Articles About "GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary" RSS

04:08 EDT 2nd July 2015 | BioPortfolio

GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary articles that have been published worldwide.

More Information about "GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary" on BioPortfolio

We have published hundreds of GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary news stories on BioPortfolio along with dozens of GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary Clinical Trials and PubMed Articles about GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary Companies in our database. You can also find out about relevant GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary Drugs and Medications on this site too.

Showing "GSK573719 GW642444 GSK573719 GW642444 GW642444 tiotropium bromide Pulmonary" PubMed Articles 1–25 of 3,400+

Extremely Relevant

Effect of inhaled tiotropium on spirometric parameters in patients with tuberculous destroyed lung.

In Korea, patients with destroyed lung due to tuberculosis (TB) account for a significant portion of those affected by chronic pulmonary function impairment. The objective of our research was to evaluate the efficacy of inhaled tiotropium bromide in TB destroyed lung.

Tiotropium bromide as add-on therapy to inhaled corticosteroids for treating asthma.

Bronchial asthma is becoming increasingly prevalent worldwide. Although first-line therapy with inhaled corticosteroids (ICS) with or without long-acting β2 agonists (LABA) has significantly improved the clinical outcomes of asthma, they cannot provide all asthmatics with good control and thus alternatives or add-on drugs are required. Tiotropium is a long-acting muscarinic antagonist that has been used to treat chronic obstructive pulmonary disease and it has been approved for treating asthma in some coun...

Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends.

Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting beta2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide and umeclidinium bromide, are administered once daily, whereas aclidinium bromide is administered every 12 hours. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24-h dur...

Effect of Tiotropium on Hyperinflation and Treadmill Exercise Tolerance in Mild-Moderate Chronic Obstructive Pulmonary Disease.

Rationale: Bronchodilator therapy represents a potentially valuable therapeutic option to increase exercise tolerance and enhance lung function in mild-to-moderate chronic obstructive pulmonary disease (COPD). Objectives: To determine effects of tiotropium on pulmonary hyperinflation and exercise tolerance in symptomatic Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 and 2 COPD patients who experienced inspiratory capacity decrease ≥100 mL during incremental and constant work rate treadmi...

Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational study.

Long-acting inhaled bronchodilators, including anticholinergic tiotropium, are recommended for the maintenance therapy of chronic obstructive pulmonary disease (COPD). It has been shown in a number of studies that treatment with tiotropium alleviates symptoms, improves exercise tolerance, health status, and reduces exacerbations in patients with moderate to very severe stage COPD.

Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.

Long acting inhaled muscarinic receptor antagonists, such as tiotropium, are widely used as bronchodilator therapy for chronic obstructive pulmonary disease (COPD). Although this class of compounds is generally considered to be safe and well tolerated in COPD patients the cardiovascular safety of tiotropium has recently been questioned. We describe a rat in vivo model that allows the concurrent assessment of muscarinic antagonist potency, bronchodilator efficacy and a potential for side effects, and we use ...

Safety, Tolerability, and Plasma Exposure of Tiotropium Respimat(®) in Children and Adults with Cystic Fibrosis.

Abstract Background: People with cystic fibrosis (CF) suffer from chronic lung disease that is often treated with a bronchodilator. This trial evaluated the pharmacokinetics, safety, and tolerability of single and multiple doses of tiotropium inhaled via the Respimat(®) Soft Mist™ Inhaler in patients with CF. Methods: Patients received a single dose (placebo, 2.5 μg, 5 μg, or 10 μg) and/or multiple doses (placebo, 2.5 μg, or 5 μg) of tiotropium daily for 28 days. Results: Ninety-two patien...

Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.

Combining bronchodilators with different mechanisms of action may improve efficacy and reduce risk of side effects compared to increasing the dose of a single agent in chronic obstructive pulmonary disease (COPD). We investigated this by combining two long-acting bronchodilators: once-daily muscarinic antagonist tiotropium and once-daily β2-agonist olodaterol.


The role of tiotropium for the treatment of asthma has not yet been clearly defined. The aim of this systematic review was to assess the efficacy and safety of tiotropium in asthma patients.

Review: Adding tiotropium to ICSs alone or with LABAs improves pulmonary function in asthma.

Tiotropium Delivered via HandiHaler or Respimat: Improvement in Health-Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease.

COPD Treatment PostersSESSION TYPE: Original Investigation PosterPRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PMPURPOSE: To assess the effects of maintenance therapy with tiotropium, a long-acting anticholinergic, on health-related quality of life (HRQoL) in COPD patients using data from 16 clinical trials.METHODS: Trials included patients with moderate-to-very severe COPD, ≥40 years, smoking history >10 pack-years. Tiotropium was delivered via HandiHaler® (Tio HH; 13 trials) or Respi...


Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease.

There is an ongoing debate on whether patients with chronic obstructive pulmonary disease (COPD) seen in real-life clinical settings are represented in randomized controlled trials (RCTs) of COPD. It is thought that the stringent inclusion and exclusion criteria of RCTs may prevent the participation of patients with specific characteristics or risk factors.

Combined Use of Olodaterol Respimat and Tiotropium HandiHaler Shows Additional Lung Function Improvement in COPD Compared With Tiotropium: Results From Two Randomized, Double-Blind Studies.

Original Investigation SlidePRESENTED ON: Monday, October 27, 2014 at 01:30 PM - 02:30 PMPURPOSE: To evaluate the bronchodilator effectiveness of combining two classes of long-acting bronchodilators (tiotropium and olodaterol) in separate devices in clinically stable patients with chronic obstructive pulmonary disease (COPD).METHODS: In two replicate, double-blind, randomized, 12-week studies, we compared the effects of (a) olodaterol 5 µg once daily (qd) (via Respimat®) in combination with tiotropium 18 ...

Comparison of Clinical Efficacy and Safety between Indacaterol and Tiotropium in COPD: Meta-Analysis of Randomized Controlled Trials.

Two once-daily inhaled bronchodilators, indacaterol and tiotropium, are widely used as first-line therapy in stable COPD patients. This study was performed to compare the clinical efficacy and safety between indacaterol and tiotropium in patients with moderate-to-severe COPD. MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched to identify all published randomized controlled trials (RCTs). The primary outcome was trough forced expiratory volume in 1 second (FEV1) at week 12. Fou...

Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.

In patients with severe asthma, tiotropium improves lung function and exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting β2 agonists. We aimed to assess the safety and efficacy of tiotropium in patients with moderate asthma who were symptomatic despite treatment with medium-dose inhaled corticosteroids.

Health Status of Patients With COPD Receiving the Combination of Olodaterol Respimat and Tiotropium HandiHaler Compared With Tiotropium: Results From Two Replicate, Randomized, Double-Blind Studies.

COPD Treatment PostersSESSION TYPE: Original Investigation PosterPRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PMPURPOSE: To determine whether combining long-acting β-agonists (LABAs) with long-acting muscarinic antagonists (LAMAs) once daily will improve the health status of patients with chronic obstructive pulmonary disease (COPD).METHODS: We report on two replicate, double-blind, randomized, 12-week studies comparing the effects of (a) the free combination of the LABA olodaterol 5 µg o...

Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease.

Umeclidinium/vilanterol (Anoro(®) Ellipta™; Laventair™) is an inhaled fixed-dose combination of a long-acting muscarinic receptor antagonist and a long-acting β2-adrenoceptor agonist. It is available in several countries, including Japan, the USA, Canada and those of the EU, where it is indicated for oral inhalation in adults with chronic obstructive pulmonary disease (COPD). Umeclidinium/vilanterol is administered once daily using the Ellipta™ multi-dose dry powder inhaler, which is regarded as eas...

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

Combining two long-acting bronchodilators with complementary mechanisms of action may provide treatment benefits to patients with chronic obstructive pulmonary disease (COPD) that are greater than those derived from either treatment alone. The efficacy and safety of a fixed-dose combination (FDC) of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting β2-agonist, in patients with moderate to severe COPD are presented.

Effectiveness of a home-based pulmonary rehabilitation programme in pulmonary function and health related quality of life for patients with pulmonary tuberculosis: a pilot study.

Patients with Pulmonary Tuberculosis (PTB) often develop impairment in pulmonary function due to anatomical changes secondary to the illness. Physiotherapy in the form of pulmonary rehabilitation has been advocated.

Pulmonary Hypertension due to Fibrosing Mediastinitis Treated Successfully With Stenting of Pulmonary Vein Stenoses.

We describe a patient with fibrosing mediastinitis after childhood histoplasmosis who presented with severe pulmonary hypertension secondary to pulmonary vein stenoses. Stenting of 2 stenosed pulmonary veins via a transseptal approach resulted in an immediate decrease in systolic pulmonary artery pressure from 90 to 68 mm Hg and improvement in dyspnea and cardiac index, which was sustained at 6 months. This case highlights the importance of routinely assessing the pulmonary veins during workup for pulmonary...

A critical evaluation of bioimpedance spectroscopy analysis in estimating body composition during GH treatment: comparison with bromide dilution and dual X-ray absorptiometry.

Objective: To compare estimates by Bioimpedance Spectroscopy Analysis (BIS) of extracellular water (ECW), fat mass (FM), and fat free mass (FFM) against standard techniques of bromide dilution and DXA during intervention that causes significant changes in water compartments and body composition. Methods: Body composition analysis using BIS, bromide dilution, and DXA was performed in 71 healthy recreational athletes (43 men, 28 women; aged 18-40 years; BMI 24±0.4 kg/m2) who participated in a double-blinded,...

An Octogenarian Diagnosed With Idiopathic Pulmonary Artery Dilatation.

Pulmonary Vascular Disease CasesSESSION TYPE: Affiliate Case Report SlidePRESENTED ON: Monday, October 27, 2014 at 03:15 PM - 04:15 PMINTRODUCTION: Pulmonary artery dilatation is mostly associated with both primary and secondary pulmonary hypertension, connective tissue diseases, pulmonary valve stenosis and congenital heart disease. Idiopathic pulmonary artery dilatation (IPAD) is a rare entity in the literature.

Seasonal Variations in Mortality and Exacerbations in Patients With Chronic Obstructive Pulmonary Disease During the TIOSPIR Trial.

COPD Exacerbation RiskSESSION TYPE: Original Investigation SlidePRESENTED ON: Wednesday, October 29, 2014 at 02:45 PM - 04:15 PMPURPOSE: To examine seasonal variations in mortality and exacerbations in COPD patients in the TIOtropium Safety and Performance In Respimat® (TIOSPIR®) trial (NCT01126437).

Can echocardiographically estimated pulmonary arterial elastance be a non-invasive predictor of pulmonary vascular resistance?

Measurement of pulmonary vascular resistance (PVR) is essential in evaluating a patient with pulmonary hypertension.

Pulmonary Artery Sarcoma: Not Every Filling Defect Is a Pulmonary Thromboembolism.

Pulmonary Vascular Case Report PostersSESSION TYPE: Affiliate Case Report PosterPRESENTED ON: Tuesday, October 28, 2014 at 01:30 PM - 02:30 PMINTRODUCTION: Pulmonary artery sarcoma (PAS) is a rare malignancy arising from the mesenchymal cells of the intima of pulmonary artery.It is often misdiagnosed as pulmonary thromboembolism (PTE), as both diseases initially appear as intraluminal 'filling defects' in the pulmonary artery on contrast-enhanced CT scans. We describe a patient initially misdiagnosed as PTE...


PubMed Database Quicklinks